HC Wainwright & Co. Reiterates Buy on SpringWorks Therapeutics, Maintains $74 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating on SpringWorks Therapeutics (NASDAQ:SWTX) with a maintained price target of $74.
May 06, 2024 | 10:35 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on SpringWorks Therapeutics with a $74 price target.
The reiteration of a Buy rating by a reputable analyst firm like HC Wainwright & Co., along with a significant price target of $74, suggests a strong bullish outlook for SpringWorks Therapeutics. This endorsement is likely to instill confidence in investors, potentially driving up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100